The Global Swine Vaccines Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 6.1% to reach USD 2.7 billion by 2034.
Market growth is driven by the rising global consumption and production of pork, one of the most widely consumed meats worldwide. Ensuring the health and productivity of swine herds has become a priority as the livestock industry expands to meet the growing demand for animal protein, fueled by rising populations, urbanization, and shifting dietary preferences. Intensification of swine production for higher efficiency and yield emphasizes preventive healthcare, with vaccines playing a critical role in minimizing disease risks that can impact animal survival and economic returns. Additionally, food security remains a pressing concern in regions heavily reliant on pork, making disease prevention through vaccination crucial to maintain stable supply chains, prevent price spikes, and safeguard the availability of this key protein source.
The inactivated or killed vaccines segment held a 57.6% share and was valued at USD 862.4 million in 2024. These vaccines are preferred for their proven safety, stability, and long shelf life, making them ideal for large-scale vaccination programs, particularly in areas with established cold chain systems. Their reliability in preventing common swine diseases ensures ongoing demand across global markets.
The viral infections segment generated USD 990.6 million in 2024 and is expected to grow at a CAGR of 6.3% through 2034. This segment’s growth is driven by the high prevalence and economic impact of contagious viral diseases that affect swine, including those that cause reproductive failures, growth retardation, and significant financial losses. High transmissibility in densely populated farms makes vaccination the most effective preventive strategy, sustaining this segment’s market dominance.
North America Swine Vaccines Market generated USD 650.8 million in 2024 and is expected to reach USD 1.1 billion by 2034, growing at a CAGR of 5.6% between 2025 and 2034. The region’s leadership is supported by advanced livestock management practices, robust veterinary healthcare infrastructure, and strong demand for high-quality pork. Major commercial swine operations, frequent outbreaks of contagious diseases, and the presence of leading animal health companies drive vaccine adoption and reinforce North America’s dominant market position.
Key players operating in the Global Swine Vaccines Market include Addison Biological Laboratory, Bioveta, a.s., Boehringer Ingelheim, Ceva Santé Animale, Colorado Serum Company, Elanco Animal Health Incorporated, HIPRA S.A., Indian Immunologicals, Merck, biogénesis Bagó, Vaxxinova (EW Group), Virbac, and Zoetis. Companies in the Swine Vaccines Market strengthen their presence by investing in research and development to create innovative, high-efficacy vaccines targeting emerging viral and bacterial swine diseases. They expand global reach through strategic partnerships, mergers, and acquisitions, while improving supply chain efficiency to ensure vaccine availability in key regions. Firms focus on educating swine producers about preventive healthcare benefits, optimizing cold chain logistics, and offering value-added services such as herd health monitoring programs.
This product will be delivered within 2-4 business days.
Market growth is driven by the rising global consumption and production of pork, one of the most widely consumed meats worldwide. Ensuring the health and productivity of swine herds has become a priority as the livestock industry expands to meet the growing demand for animal protein, fueled by rising populations, urbanization, and shifting dietary preferences. Intensification of swine production for higher efficiency and yield emphasizes preventive healthcare, with vaccines playing a critical role in minimizing disease risks that can impact animal survival and economic returns. Additionally, food security remains a pressing concern in regions heavily reliant on pork, making disease prevention through vaccination crucial to maintain stable supply chains, prevent price spikes, and safeguard the availability of this key protein source.
The inactivated or killed vaccines segment held a 57.6% share and was valued at USD 862.4 million in 2024. These vaccines are preferred for their proven safety, stability, and long shelf life, making them ideal for large-scale vaccination programs, particularly in areas with established cold chain systems. Their reliability in preventing common swine diseases ensures ongoing demand across global markets.
The viral infections segment generated USD 990.6 million in 2024 and is expected to grow at a CAGR of 6.3% through 2034. This segment’s growth is driven by the high prevalence and economic impact of contagious viral diseases that affect swine, including those that cause reproductive failures, growth retardation, and significant financial losses. High transmissibility in densely populated farms makes vaccination the most effective preventive strategy, sustaining this segment’s market dominance.
North America Swine Vaccines Market generated USD 650.8 million in 2024 and is expected to reach USD 1.1 billion by 2034, growing at a CAGR of 5.6% between 2025 and 2034. The region’s leadership is supported by advanced livestock management practices, robust veterinary healthcare infrastructure, and strong demand for high-quality pork. Major commercial swine operations, frequent outbreaks of contagious diseases, and the presence of leading animal health companies drive vaccine adoption and reinforce North America’s dominant market position.
Key players operating in the Global Swine Vaccines Market include Addison Biological Laboratory, Bioveta, a.s., Boehringer Ingelheim, Ceva Santé Animale, Colorado Serum Company, Elanco Animal Health Incorporated, HIPRA S.A., Indian Immunologicals, Merck, biogénesis Bagó, Vaxxinova (EW Group), Virbac, and Zoetis. Companies in the Swine Vaccines Market strengthen their presence by investing in research and development to create innovative, high-efficacy vaccines targeting emerging viral and bacterial swine diseases. They expand global reach through strategic partnerships, mergers, and acquisitions, while improving supply chain efficiency to ensure vaccine availability in key regions. Firms focus on educating swine producers about preventive healthcare benefits, optimizing cold chain logistics, and offering value-added services such as herd health monitoring programs.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies featured in this Swine Vaccines market report include:- Addison Biological Laboratory
- Bioveta, a.s.
- Boehringer Ingelheim
- Ceva Santé Animale
- Colorado Serum Company
- Elanco Animal Health Incorporated
- HIPRA S.A.
- Indian Immunologicals
- Merck
- biogénesis Bagó
- Vaxxinova (EW Group)
- Virbac
- Zoetis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 164 |
| Published | November 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 1.5 Billion |
| Forecasted Market Value ( USD | $ 2.7 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
